Actively Recruiting
Study of Zedoresertib with Temozolomide, with or without Radiotherapy, in Adults with Glioblastoma or Astrocytoma
Led by Debiopharm International SA · Updated on 2026-10-28
116
Participants Needed
16
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and efficacy of zedoresertib combined with temozolomide TMZ, with or without radiotherapy RT, in adults with glioblastoma GBM. This study includes a Phase 1 dose escalation to identify dose-limiting toxicities and a dose expansion to find the recommended dose. Phase 2 will assess the effectiveness of zedoresertib at this dose combined with TMZ compared to standard treatment in adults with GBM. Participants in different study arms receive intermittent escalating doses of zedoresertib capsules combined with TMZ capsules in 28-day cycles for up to two years, or combined with TMZ and RT for up to six weeks. Phase 1 includes three arms, but Arm B involving RT has been permanently halted for safety reasons. Phase 2 will start after determining the recommended dose from Phase 1 and will focus on zedoresertib plus TMZ treatment. During the study, participants will have regular visits for treatment and monitoring. Researchers will assess dose-limiting toxicities, adverse events, laboratory tests, heart function tests ECG and echocardiogram, and performance status. Tumor size will be measured by MRI using RANO criteria. Pharmacokinetics and pharmacodynamics will be evaluated through blood samples. Survival and disease progression will be tracked up to approximately 66 months. Safety will be monitored up to 30 days after treatment ends.
CONDITIONS
Brief Title
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Research Team
D
Debiopharm International S.A
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here